| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Belinda J Cridge, Rhonda J Rosengre. Critical appraisal of the potential use of cannabinoids in cancer management. Cancer management and research. vol 5. 2013-09-20. PMID:24039449. |
originally derived from the plant cannabis sativa, there are now a number of endo-, phyto- and synthetic cannabinoids available. |
2013-09-20 |
2023-08-12 |
Not clear |
| R Andrew Sewell, Ashley Schnakenberg, Jacqueline Elander, Rajiv Radhakrishnan, Ashley Williams, Patrick D Skosnik, Brian Pittman, Mohini Ranganathan, D Cyril D'Souz. Acute effects of THC on time perception in frequent and infrequent cannabis users. Psychopharmacology. vol 226. issue 2. 2013-09-10. PMID:23179965. |
few studies have included both time estimation and production tasks, few control for subvocal counting, most had small sample sizes, some did not record subjects' cannabis use, many tested only one dose, and used either oral or inhaled administration of Δ⁹-tetrahydrocannabinol (thc), leading to variable pharmacokinetics, and some used whole-plant cannabis containing cannabinoids other than thc. |
2013-09-10 |
2023-08-12 |
human |
| Elizabeth A Penner, Hannah Buettner, Murray A Mittlema. The impact of marijuana use on glucose, insulin, and insulin resistance among US adults. The American journal of medicine. vol 126. issue 7. 2013-08-28. PMID:23684393. |
epidemiologic studies have found lower prevalence rates of obesity and diabetes mellitus in marijuana users compared with people who have never used marijuana, suggesting a relationship between cannabinoids and peripheral metabolic processes. |
2013-08-28 |
2023-08-12 |
Not clear |
| Zerrin Ataka. Cannabis, a complex plant: different compounds and different effects on individuals. Therapeutic advances in psychopharmacology. vol 2. issue 6. 2013-08-28. PMID:23983983. |
in this article we first provide an overview of the biochemical basis of cannabis research by examining the different effects of the two main compounds of the plant and the endocannabinoid system, and then go on to review available information on the possible factors explaining variation of its effects upon different individuals. |
2013-08-28 |
2023-08-12 |
Not clear |
| Karl B Scheidweiler, David M Schwope, Erin L Karschner, Nathalie A Desrosiers, David A Gorelick, Marilyn A Huesti. In vitro stability of free and glucuronidated cannabinoids in blood and plasma following controlled smoked cannabis. Clinical chemistry. vol 59. issue 7. 2013-08-27. PMID:23519966. |
in vitro stability of free and glucuronidated cannabinoids in blood and plasma following controlled smoked cannabis. |
2013-08-27 |
2023-08-12 |
Not clear |
| T Hermanns-Lé, P Delvenne, G E Piérard, A F Rousseau, C Piérard-franchimon. [Risking the skin for some joints]. Revue medicale de Liege. vol 68. issue 5-6. 2013-08-27. PMID:23888582. |
marijuana, cannabis, hemp designate some plants and their extracts enriched in cannabinoids including change 9-tetrahydrocannabinol (thc). |
2013-08-27 |
2023-08-12 |
Not clear |
| Vincenzo Micale, Vincenzo Di Marzo, Alexandra Sulcova, Carsten T Wotjak, Filippo Drag. Endocannabinoid system and mood disorders: priming a target for new therapies. Pharmacology & therapeutics. vol 138. issue 1. 2013-08-26. PMID:23261685. |
the endocannabinoid system (ecs), comprising two g protein-coupled receptors (the cannabinoid receptors 1 and 2 [cb1 and cb2] for marijuana's psychoactive principle ∆(9)-tetrahydrocannabinol [∆(9)-thc]), their endogenous small lipid ligands (namely anandamide [aea] and 2-arachidonoylglycerol [2-ag], also known as endocannabinoids), and the proteins for endocannabinoid biosynthesis and degradation, has been suggested as a pro-homeostatic and pleiotropic signaling system activated in a time- and tissue-specific way during physiopathological conditions. |
2013-08-26 |
2023-08-12 |
Not clear |
| Vincenzo Micale, Vincenzo Di Marzo, Alexandra Sulcova, Carsten T Wotjak, Filippo Drag. Endocannabinoid system and mood disorders: priming a target for new therapies. Pharmacology & therapeutics. vol 138. issue 1. 2013-08-26. PMID:23261685. |
however, the realization that endocannabinoids, and aea in particular, also act at other molecular targets, and that these mediators can be deactivated by redundant pathways, has recently led to question the efficacy of such approach, thus opening the way to new multi-target therapeutic strategies, and to the use of non-psychotropic cannabinoids, such as cannabidiol (cbd), which act via several parallel mechanisms, including indirect interactions with the ecs. |
2013-08-26 |
2023-08-12 |
Not clear |
| Kim Wild, Hugh Wilso. Cannabinoid hyperemesis. BMJ case reports. vol 2010. 2013-08-21. PMID:22778182. |
a diagnosis of cannabinoid hyperemesis was made and her symptoms resolved after treatment with intravenous fluids, antiemetics and abstinence from cannabis. |
2013-08-21 |
2023-08-12 |
Not clear |
| Antonio García-Merin. Endocannabinoid system modulator use in everyday clinical practice in the UK and Spain. Expert review of neurotherapeutics. vol 13. issue 3 Suppl 1. 2013-08-21. PMID:23369054. |
sativex® (gw pharmaceuticals plc, porton down, uk; laboratorios almirall, sa, barcelona, spain) is a unique cannabinoid-based medicine with two main active ingredients; 9-δ-tetrahydrocannabinol, which acts mainly on cannabinoid 1 receptors in the cns and plays a key role in the modulation of spasticity and spasms, and cannabidiol, which has different properties, including minimization of the psychoactivity associated with 9-δ-tetrahydrocannabinol. |
2013-08-21 |
2023-08-12 |
Not clear |
| Peter Flachenecke. A new multiple sclerosis spasticity treatment option: effect in everyday clinical practice and cost-effectiveness in Germany. Expert review of neurotherapeutics. vol 13. issue 3 Suppl 1. 2013-08-21. PMID:23369055. |
sativex® (gw pharmaceuticals plc, porton down, uk; laboratorios almirall, sa, barcelona, spain), a cannabinoid oromucosal spray containing a 1:1 ratio of 9-δ-tetrahydrocannabinol and cannabidiol, has been licensed in germany since july 2011 as add-on therapy for moderate-to-severe multiple sclerosis (ms) treatment-resistant spasticity symptoms. |
2013-08-21 |
2023-08-12 |
Not clear |
| Fabiana Piscitelli, Vincenzo Di Marz. "Redundancy" of endocannabinoid inactivation: new challenges and opportunities for pain control. ACS chemical neuroscience. vol 3. issue 5. 2013-08-20. PMID:22860203. |
however, new strategies, including the rediscovery of "dirty drugs", and the use of certain natural products (including non-thc cannabis constituents), are emerging that might allow us to make a virtue of necessity and exploit endocannabinoid redundancy to develop new analgesics. |
2013-08-20 |
2023-08-12 |
Not clear |
| Jami L Hickey, Joanne C Witsil, Mark B Mycy. Haloperidol for treatment of cannabinoid hyperemesis syndrome. The American journal of emergency medicine. vol 31. issue 6. 2013-08-20. PMID:23583118. |
cannabinoid hyperemesis syndrome (chs) is a condition characterized by cyclical vomiting without other identifiable cause in patients with chronic cannabis use. |
2013-08-20 |
2023-08-12 |
Not clear |
| Emanuela Esposito, Salvatore Cuzzocre. Palmitoylethanolamide is a new possible pharmacological treatment for the inflammation associated with trauma. Mini reviews in medicinal chemistry. vol 13. issue 2. 2013-08-19. PMID:22697514. |
interest in this compound faded, however, until the discovery that one of its structural analogs, anandamide (arachidonoylethanolamide), serves as an endogenous ligand for cannabinoid receptors, the molecular target of Δ9-tetrahydrocannabinol in marijuana. |
2013-08-19 |
2023-08-12 |
mouse |
| Viviana Trezza, Patrizia Campolong. The endocannabinoid system as a possible target to treat both the cognitive and emotional features of post-traumatic stress disorder (PTSD). Frontiers in behavioral neuroscience. vol 7. 2013-08-16. PMID:23950739. |
clinical findings showing a relationship between cannabis use and ptsd, as well as changes in endocannabinoid activity in ptsd patients, further suggest the existence of a link between endocannabinoids and maladaptive brain changes after trauma exposure. |
2013-08-16 |
2023-08-12 |
Not clear |
| Nizar Happyana, Sara Agnolet, Remco Muntendam, Annie Van Dam, Bernd Schneider, Oliver Kayse. Analysis of cannabinoids in laser-microdissected trichomes of medicinal Cannabis sativa using LCMS and cryogenic NMR. Phytochemistry. vol 87. 2013-08-08. PMID:23280038. |
analysis of cannabinoids in laser-microdissected trichomes of medicinal cannabis sativa using lcms and cryogenic nmr. |
2013-08-08 |
2023-08-12 |
Not clear |
| Nizar Happyana, Sara Agnolet, Remco Muntendam, Annie Van Dam, Bernd Schneider, Oliver Kayse. Analysis of cannabinoids in laser-microdissected trichomes of medicinal Cannabis sativa using LCMS and cryogenic NMR. Phytochemistry. vol 87. 2013-08-08. PMID:23280038. |
trichomes, especially the capitate-stalked glandular hairs, are well known as the main sites of cannabinoid and essential oil production of cannabis sativa. |
2013-08-08 |
2023-08-12 |
Not clear |
| M Mecha, A S Torrao, L Mestre, F J Carrillo-Salinas, R Mechoulam, C Guaz. Cannabidiol protects oligodendrocyte progenitor cells from inflammation-induced apoptosis by attenuating endoplasmic reticulum stress. Cell death & disease. vol 3. 2013-07-23. PMID:22739983. |
cannabidiol (cbd) is the most abundant cannabinoid in cannabis sativa that has no psychoactive properties. |
2013-07-23 |
2023-08-12 |
Not clear |
| Dolores Hernán Pérez de la Ossa, Mar Lorente, Maria Esther Gil-Alegre, Sofía Torres, Elena García-Taboada, María Del Rosario Aberturas, Jesús Molpeceres, Guillermo Velasco, Ana Isabel Torres-Suáre. Local delivery of cannabinoid-loaded microparticles inhibits tumor growth in a murine xenograft model of glioblastoma multiforme. PloS one. vol 8. issue 1. 2013-07-19. PMID:23349970. |
cannabinoids, the active components of marijuana and their derivatives, are currently investigated due to their potential therapeutic application for the management of many different diseases, including cancer. |
2013-07-19 |
2023-08-12 |
mouse |
| Dolores Hernán Pérez de la Ossa, Mar Lorente, Maria Esther Gil-Alegre, Sofía Torres, Elena García-Taboada, María Del Rosario Aberturas, Jesús Molpeceres, Guillermo Velasco, Ana Isabel Torres-Suáre. Local delivery of cannabinoid-loaded microparticles inhibits tumor growth in a murine xenograft model of glioblastoma multiforme. PloS one. vol 8. issue 1. 2013-07-19. PMID:23349970. |
although there are several pharmaceutical preparations that permit the oral administration of thc or its analogue nabilone or the oromucosal delivery of a thc- and cbd-enriched cannabis extract, the systemic administration of cannabinoids has several limitations in part derived from the high lipophilicity exhibited by these compounds. |
2013-07-19 |
2023-08-12 |
mouse |